- Home
- SNTG vs GLMD Comparison
SNTG vs GLMD Comparison
Compare SNTG & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- GLMD
- Stock Information
- Founded
- SNTG 2009
- GLMD 2000
- Country
- SNTG China
- GLMD Israel
- Employees
- SNTG N/A
- GLMD N/A
- Industry
- SNTG Finance: Consumer Services
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- SNTG Finance
- GLMD Health Care
- Exchange
- SNTG Nasdaq
- GLMD Nasdaq
- Market Cap
- SNTG 8.2M
- GLMD 6.6M
- IPO Year
- SNTG 2021
- GLMD 2014
- Fundamental
- Price
- SNTG $2.07
- GLMD $1.18
- Analyst Decision
- SNTG
- GLMD Hold
- Analyst Count
- SNTG 0
- GLMD 1
- Target Price
- SNTG N/A
- GLMD N/A
- AVG Volume (30 Days)
- SNTG 15.0K
- GLMD 65.7K
- Earning Date
- SNTG 12-16-2025
- GLMD 11-14-2025
- Dividend Yield
- SNTG N/A
- GLMD N/A
- EPS Growth
- SNTG N/A
- GLMD N/A
- EPS
- SNTG N/A
- GLMD N/A
- Revenue
- SNTG $107,507.00
- GLMD N/A
- Revenue This Year
- SNTG N/A
- GLMD N/A
- Revenue Next Year
- SNTG N/A
- GLMD N/A
- P/E Ratio
- SNTG N/A
- GLMD N/A
- Revenue Growth
- SNTG N/A
- GLMD N/A
- 52 Week Low
- SNTG $1.43
- GLMD $1.15
- 52 Week High
- SNTG $12.70
- GLMD $3.61
- Technical
- Relative Strength Index (RSI)
- SNTG 35.11
- GLMD 32.65
- Support Level
- SNTG $1.90
- GLMD $1.16
- Resistance Level
- SNTG $2.33
- GLMD $1.27
- Average True Range (ATR)
- SNTG 0.15
- GLMD 0.08
- MACD
- SNTG -0.05
- GLMD -0.02
- Stochastic Oscillator
- SNTG 11.21
- GLMD 0.00
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.